JP2013508281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508281A5 JP2013508281A5 JP2012534309A JP2012534309A JP2013508281A5 JP 2013508281 A5 JP2013508281 A5 JP 2013508281A5 JP 2012534309 A JP2012534309 A JP 2012534309A JP 2012534309 A JP2012534309 A JP 2012534309A JP 2013508281 A5 JP2013508281 A5 JP 2013508281A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- pyridin
- hydroxy
- oxo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 67
- 239000001257 hydrogen Substances 0.000 claims 67
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 41
- 150000002431 hydrogen Chemical class 0.000 claims 26
- 125000003545 alkoxy group Chemical group 0.000 claims 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 21
- 125000004438 haloalkoxy group Chemical group 0.000 claims 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 20
- 125000003282 alkyl amino group Chemical group 0.000 claims 19
- 125000004663 dialkyl amino group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 16
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 16
- 150000001540 azides Chemical class 0.000 claims 14
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- -1 cyano, amino Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 208000019695 Migraine disease Diseases 0.000 claims 4
- 206010027599 migraine Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- UGUUDTWORXNLAK-UHFFFAOYSA-N azidoalcohol Chemical compound ON=[N+]=[N-] UGUUDTWORXNLAK-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 2
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 claims 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 claims 2
- 230000005796 circulatory shock Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000011010 flushing procedure Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 230000024883 vasodilation Effects 0.000 claims 2
- MBACCAVFVLZDPN-UHFFFAOYSA-N (2-oxo-3H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate Chemical compound N1(CCCCC1)C(=O)ON1C(NC2=NC=CC=C21)=O MBACCAVFVLZDPN-UHFFFAOYSA-N 0.000 claims 1
- ZUXYCGUNLBKKQW-FHLBMDLUSA-N 1-[1-[2-[(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl]acetyl]piperidin-4-yl]-3h-imidazo[4,5-b]pyridin-2-one Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@@H](CC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)N)=CC=CC(F)=C1F ZUXYCGUNLBKKQW-FHLBMDLUSA-N 0.000 claims 1
- IDBLZYJFOOVSBY-QRJOEMBSSA-N [(5r,6s,9r)-6-(2,3-difluorophenyl)-5-hydroxy-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@H]2[C@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)O)=CC=CC(F)=C1F IDBLZYJFOOVSBY-QRJOEMBSSA-N 0.000 claims 1
- IDBLZYJFOOVSBY-KPCPBYSCSA-N [(5s,6r,9r)-6-(2,3-difluorophenyl)-5-hydroxy-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@@H]2[C@@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)O)=CC=CC(F)=C1F IDBLZYJFOOVSBY-KPCPBYSCSA-N 0.000 claims 1
- KRNAOFGYEFKHPB-ANJVHQHFSA-N [(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)N)=CC=CC(F)=C1F KRNAOFGYEFKHPB-ANJVHQHFSA-N 0.000 claims 1
- OEVUEGRUSLKBSD-ZTCOLXNVSA-N [(5s,6s,9r)-5-amino-6-(3,5-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)N)=CC(F)=CC(F)=C1 OEVUEGRUSLKBSD-ZTCOLXNVSA-N 0.000 claims 1
- DNBQIQVKRDRNJO-ANJVHQHFSA-N [(5s,6s,9r)-5-azido-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound FC1=CC=CC([C@H]2[C@@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)N=[N+]=[N-])=C1F DNBQIQVKRDRNJO-ANJVHQHFSA-N 0.000 claims 1
- IDBLZYJFOOVSBY-FKRCVWNDSA-N [(5s,6s,9r)-6-(2,3-difluorophenyl)-5-hydroxy-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)O)=CC=CC(F)=C1F IDBLZYJFOOVSBY-FKRCVWNDSA-N 0.000 claims 1
- ZHBAFDFGEDSALF-ZWSUVBHBSA-N [(5s,6s,9r)-6-(3,5-difluorophenyl)-5-hydroxy-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)O)=CC(F)=CC(F)=C1 ZHBAFDFGEDSALF-ZWSUVBHBSA-N 0.000 claims 1
- RRIWMCIJNHEEBZ-CBCWYDDASA-N [(6s,8r,9s)-6-(2,3-difluorophenyl)-8-hydroxy-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@@H]2C[C@H]([C@H](C3=NC=CC=C3C2)OC(=O)N2CCC(CC2)N2C(NC3=NC=CC=C32)=O)O)=CC=CC(F)=C1F RRIWMCIJNHEEBZ-CBCWYDDASA-N 0.000 claims 1
- SEDRSDAVRCXOAF-DFHRPNOPSA-N [(6s,9r)-6-(2,3-difluorophenyl)-6-hydroxy-5,7,8,9-tetrahydrocyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@]2(CC3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)O)=CC=CC(F)=C1F SEDRSDAVRCXOAF-DFHRPNOPSA-N 0.000 claims 1
- WLJCNLRHCYLSIH-LMNIDFBRSA-N [(9r)-6-(2,3-difluorophenyl)-5-oxo-6,7,8,9-tetrahydrocyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound FC1=CC=CC(C2C(C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)=O)=C1F WLJCNLRHCYLSIH-LMNIDFBRSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- SBNGFOZUAVWKBR-PNEDJKHOSA-N tert-butyl n-[(5s,6s,9r)-6-(2,3-difluorophenyl)-9-[2-oxo-2-[4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidin-1-yl]ethyl]-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-5-yl]carbamate Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@@H](CC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)NC(=O)OC(C)(C)C)=CC=CC(F)=C1F SBNGFOZUAVWKBR-PNEDJKHOSA-N 0.000 claims 1
- KSODXXHVDMUJTG-XCRHUMRWSA-N tert-butyl n-[(5s,6s,9r)-9-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-5-yl]carbamate Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@H](N)CC2)NC(=O)OC(C)(C)C)=CC=CC(F)=C1F KSODXXHVDMUJTG-XCRHUMRWSA-N 0.000 claims 1
- 0 C*1c2cccnc2C(*C(*)=O)C(*)(*)C(*)(*)C1(C)* Chemical compound C*1c2cccnc2C(*C(*)=O)C(*)(*)C(*)(*)C1(C)* 0.000 description 3
- DKOVETTYBHNFNO-UHFFFAOYSA-O CC(C)N(CCc(c(N1)ccc2)[n+]2O)C1=O Chemical compound CC(C)N(CCc(c(N1)ccc2)[n+]2O)C1=O DKOVETTYBHNFNO-UHFFFAOYSA-O 0.000 description 1
- BKEFAAUTUUQOMM-UHFFFAOYSA-N CC(C)N(CCc1ncccc1N1)C1=O Chemical compound CC(C)N(CCc1ncccc1N1)C1=O BKEFAAUTUUQOMM-UHFFFAOYSA-N 0.000 description 1
- BVLLDWVRHRWMOK-UHFFFAOYSA-N CC1(C)C=C(CN(C)C(N2)=O)C2=NC=C1 Chemical compound CC1(C)C=C(CN(C)C(N2)=O)C2=NC=C1 BVLLDWVRHRWMOK-UHFFFAOYSA-N 0.000 description 1
- FDQDEYVZTNVCIF-UHFFFAOYSA-O CCN(CCc(c(N1)ccc2)[n+]2O)C1=O Chemical compound CCN(CCc(c(N1)ccc2)[n+]2O)C1=O FDQDEYVZTNVCIF-UHFFFAOYSA-O 0.000 description 1
- CHZRTXKKKOYGJO-UHFFFAOYSA-N CN(CCc1ccccc1N1)C1=O Chemical compound CN(CCc1ccccc1N1)C1=O CHZRTXKKKOYGJO-UHFFFAOYSA-N 0.000 description 1
- VBYNMZORUPNRKR-UHFFFAOYSA-N CN(Cc1c(N2)nccc1)C2=O Chemical compound CN(Cc1c(N2)nccc1)C2=O VBYNMZORUPNRKR-UHFFFAOYSA-N 0.000 description 1
- FBKOMTLPDDPCSE-UHFFFAOYSA-O CN(Cc1c[n+](=C)ccc1N1)C1=O Chemical compound CN(Cc1c[n+](=C)ccc1N1)C1=O FBKOMTLPDDPCSE-UHFFFAOYSA-O 0.000 description 1
- PYEHNKXDXBNHQQ-UHFFFAOYSA-N CN(c1ccccc1N1)C1=O Chemical compound CN(c1ccccc1N1)C1=O PYEHNKXDXBNHQQ-UHFFFAOYSA-N 0.000 description 1
- JWBRNYGXJYMMSI-UHFFFAOYSA-N CN(c1cccnc1N1)C1=O Chemical compound CN(c1cccnc1N1)C1=O JWBRNYGXJYMMSI-UHFFFAOYSA-N 0.000 description 1
- HHQIYFYEJOWYJM-POEMVANMSA-N C[NH+2]/C=C(/CN(C)C(N1)=O)\C1=C/C=C Chemical compound C[NH+2]/C=C(/CN(C)C(N1)=O)\C1=C/C=C HHQIYFYEJOWYJM-POEMVANMSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25147709P | 2009-10-14 | 2009-10-14 | |
| US61/251,477 | 2009-10-14 | ||
| PCT/US2010/052433 WO2011046997A1 (en) | 2009-10-14 | 2010-10-13 | Cgrp receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015092727A Division JP6109874B2 (ja) | 2009-10-14 | 2015-04-30 | Ｃｇｒｐ受容体アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508281A JP2013508281A (ja) | 2013-03-07 |
| JP2013508281A5 true JP2013508281A5 (enExample) | 2013-11-28 |
| JP5836279B2 JP5836279B2 (ja) | 2015-12-24 |
Family
ID=43242489
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534309A Active JP5836279B2 (ja) | 2009-10-14 | 2010-10-13 | Ｃｇｒｐ受容体アンタゴニスト |
| JP2015092727A Active JP6109874B2 (ja) | 2009-10-14 | 2015-04-30 | Ｃｇｒｐ受容体アンタゴニスト |
| JP2017043761A Active JP6258537B2 (ja) | 2009-10-14 | 2017-03-08 | Ｃｇｒｐ受容体アンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015092727A Active JP6109874B2 (ja) | 2009-10-14 | 2015-04-30 | Ｃｇｒｐ受容体アンタゴニスト |
| JP2017043761A Active JP6258537B2 (ja) | 2009-10-14 | 2017-03-08 | Ｃｇｒｐ受容体アンタゴニスト |
Country Status (35)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314117B2 (en) * | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) * | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| US8748429B2 (en) * | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| PT3254681T (pt) * | 2012-02-27 | 2019-10-01 | Bristol Myers Squibb Co | Sal de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9- tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3- dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1- carboxilato |
| WO2013169563A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| TW201718574A (zh) * | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Ｃｇｒｐ受體拮抗劑 |
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| EP4088720B1 (en) | 2018-03-25 | 2025-09-03 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant for cgrp related disorders |
| CN114805206B (zh) * | 2021-01-27 | 2025-01-14 | 奥锐特药业(天津)有限公司 | 高光学纯度瑞美吉泮中间体的工业化制备方法 |
| WO2022185224A1 (en) | 2021-03-02 | 2022-09-09 | Mark Hasleton | Treatment and/or reduction of occurrence of migraine |
| US20250109188A1 (en) | 2021-08-24 | 2025-04-03 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| CN116554164B (zh) * | 2022-01-27 | 2025-10-03 | 奥锐特药业(天津)有限公司 | 一种瑞美吉泮的制备方法 |
| WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
| CN116478211B (zh) * | 2022-04-19 | 2023-10-24 | 石家庄迪斯凯威医药科技有限公司 | 一种新型cgrp受体拮抗剂及其用途 |
| CN115060824B (zh) * | 2022-06-14 | 2024-03-12 | 浙江宏元药业股份有限公司 | 一种瑞米吉泮中间体对映异构体杂质的液相色谱检测方法 |
| WO2024022434A1 (zh) * | 2022-07-29 | 2024-02-01 | 熙源安健医药（上海）有限公司 | 吡啶并环庚烷类衍生物及其制备方法和用途 |
| CN115677694A (zh) * | 2022-11-30 | 2023-02-03 | 南通常佑药业科技有限公司 | 一种瑞美吉泮的合成方法 |
| WO2024180562A1 (en) * | 2023-03-02 | 2024-09-06 | Natco Pharma Limited | A process for the preparation of pure crystalline rimegepant and its salts thereof |
| CN116768938B (zh) * | 2023-05-17 | 2025-11-11 | 南京艾德凯腾生物医药有限责任公司 | 一种铁催化剂及瑞美吉泮中间体的制备方法 |
| CN119661518A (zh) * | 2023-09-21 | 2025-03-21 | 成都康弘药业集团股份有限公司 | 一种治疗cgrp相关障碍的小分子药物 |
| CN117486798B (zh) * | 2023-12-21 | 2025-02-07 | 南京威凯尔生物医药科技有限公司 | 一种瑞美吉泮中间体盐酸盐的晶型及其制备方法 |
| WO2025193980A2 (en) * | 2024-03-13 | 2025-09-18 | CNS Biosciences, Inc. | Method of treating neuropathic pain using an anti-cgrp inhibitor |
| CN119707808B (zh) * | 2024-12-23 | 2025-12-05 | 上海彩迩文生化科技有限公司 | 一种制备cgrp受体拮抗剂中间体的方法 |
| CN119977885A (zh) * | 2025-04-15 | 2025-05-13 | 常州制药厂有限公司 | (5S,6S,9R)-5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5H-环庚[b]吡啶-9-醇L-酒石酸盐及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| WO2005085228A1 (ja) | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | シクロアルカノピリジン誘導体 |
| AU2005295729B2 (en) | 2004-10-13 | 2011-07-14 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US20060084708A1 (en) | 2004-10-14 | 2006-04-20 | Bayer Materialscience Llc | Rigid foams with good insulation properties and a process for the production of such foams |
| CA2584241A1 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | Cgrp receptor antagonists |
| AU2007238894A1 (en) | 2006-04-10 | 2007-10-25 | Merck Sharp & Dohme Corp. | Process for the preparation of pyridine heterocycle CGRP antagonist intermediate |
| US8044043B2 (en) * | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8314117B2 (en) * | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
-
2010
- 2010-10-12 US US12/902,714 patent/US8314117B2/en active Active
- 2010-10-13 PE PE2012000490A patent/PE20121137A1/es active IP Right Grant
- 2010-10-13 KR KR1020187018446A patent/KR101990755B1/ko active Active
- 2010-10-13 DK DK10768347.6T patent/DK2488512T3/en active
- 2010-10-13 CA CA2777518A patent/CA2777518C/en active Active
- 2010-10-13 NZ NZ599281A patent/NZ599281A/xx unknown
- 2010-10-13 MX MX2012004182A patent/MX2012004182A/es active IP Right Grant
- 2010-10-13 CN CN201080056672.4A patent/CN102656159B/zh active Active
- 2010-10-13 WO PCT/US2010/052433 patent/WO2011046997A1/en not_active Ceased
- 2010-10-13 BR BR112012008828-9A patent/BR112012008828B1/pt active IP Right Grant
- 2010-10-13 RS RS20140035A patent/RS53149B/sr unknown
- 2010-10-13 PT PT107683476T patent/PT2488512E/pt unknown
- 2010-10-13 ES ES10768347.6T patent/ES2441192T3/es active Active
- 2010-10-13 CA CA2968176A patent/CA2968176C/en active Active
- 2010-10-13 KR KR1020177018206A patent/KR101875353B1/ko active Active
- 2010-10-13 KR KR1020127012197A patent/KR101755742B1/ko active Active
- 2010-10-13 JP JP2012534309A patent/JP5836279B2/ja active Active
- 2010-10-13 EA EA201270561A patent/EA020409B1/ru not_active IP Right Cessation
- 2010-10-13 SI SI201030486T patent/SI2488512T1/sl unknown
- 2010-10-13 EP EP10768347.6A patent/EP2488512B1/en active Active
- 2010-10-13 AU AU2010306954A patent/AU2010306954B2/en active Active
- 2010-10-13 HR HRP20140111AT patent/HRP20140111T1/hr unknown
- 2010-10-13 PL PL10768347T patent/PL2488512T3/pl unknown
- 2010-10-14 TW TW099135091A patent/TWI465448B/zh active
- 2010-10-14 AR ARP100103755A patent/AR078638A1/es not_active Application Discontinuation
-
2012
- 2012-03-28 TN TNP2012000139A patent/TN2012000139A1/en unknown
- 2012-04-05 IL IL219120A patent/IL219120A/en active IP Right Grant
- 2012-04-12 CL CL2012000925A patent/CL2012000925A1/es unknown
- 2012-04-26 CO CO12068979A patent/CO6460732A2/es unknown
- 2012-05-11 ZA ZA2012/03452A patent/ZA201203452B/en unknown
- 2012-10-16 US US13/652,690 patent/US20130053570A1/en not_active Abandoned
-
2014
- 2014-02-17 SM SM201400019T patent/SMT201400019B/xx unknown
-
2015
- 2015-04-30 JP JP2015092727A patent/JP6109874B2/ja active Active
-
2017
- 2017-03-08 JP JP2017043761A patent/JP6258537B2/ja active Active
- 2017-11-13 AR ARP170103159A patent/AR110069A2/es not_active Application Discontinuation
-
2022
- 2022-07-12 CY CY2022023C patent/CY2022023I2/el unknown
- 2022-07-14 NL NL301187C patent/NL301187I2/nl unknown
- 2022-07-18 HU HUS2200033C patent/HUS2200033I1/hu unknown
- 2022-07-19 LU LU00272C patent/LUC00272I2/fr unknown
- 2022-07-22 NO NO2022033C patent/NO2022033I1/no unknown
- 2022-08-02 LT LTPA2022516C patent/LTC2488512I2/lt unknown
- 2022-08-11 FR FR22C1044C patent/FR22C1044I2/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508281A5 (enExample) | ||
| JP7418395B2 (ja) | Ｓｈｐ２ホスファターゼ阻害剤およびこれらの使用方法 | |
| AU2018255300B2 (en) | Bicyclic compounds and their use in the treatment of cancer | |
| ES2985528T3 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| KR101823488B1 (ko) | 선택적으로 치환된 퀴놀린 화합물 | |
| HRP20140111T1 (hr) | Antagonisti receptora za cgrp | |
| JP6631616B2 (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| TWI896747B (zh) | 快速加速纖維肉瘤蛋白質降解之化合物及包含其之組成物 | |
| KR101959590B1 (ko) | c-KIT 키나제 억제제로서의 화합물 및 조성물 | |
| ES2982015T3 (es) | Derivados de piperidin-4-IL azetidina como inhibidores de JAK1 | |
| JP6285918B2 (ja) | テトラヒドロピラゾロピリミジン化合物 | |
| JP6133291B2 (ja) | ピラゾロ［３，４−ｃ］ピリジン化合物と使用方法 | |
| ES2738823T3 (es) | Moduladores heterocíclicos de la síntesis de lípidos | |
| CA3005918C (en) | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof | |
| CA2942997A1 (en) | Heteroaryl syk inhibitors | |
| CA3001096A1 (en) | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | |
| JP2015521645A (ja) | ５−アザインダゾール化合物及び使用方法 | |
| TW202015677A (zh) | 用於治療疾病之新穎化合物及其醫藥組合物 | |
| CA2983342A1 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| JP2018530557A (ja) | 置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用 | |
| TW202132297A (zh) | 經取代吡啶及使用方法 | |
| CA3106131A1 (en) | P2x3 receptor antagonists | |
| AU2019363662B2 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| JP2009535429A5 (enExample) | ||
| EP4444421A2 (en) | Heterocyclic compounds as dyrk1a inhibitors |